Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cellectar Biosciences

4.80
+0.07001.48%
Post-market: 4.880.0800+1.67%16:56 EDT
Volume:238.95K
Turnover:1.18M
Market Cap:8.70M
PE:-0.21
High:5.17
Open:5.17
Low:4.61
Close:4.73
Loading ...

Cellectar Biosciences provides update on CLOVER-2 Phase 1 trial

TIPRANKS
·
11 Jun

Cellectar Biosciences Inc - Patients Receiving 55 Mci Dose Show 5.4 Months Pfs, 8.6 Months Os, Ongoing

THOMSON REUTERS
·
11 Jun

Cellectar Biosciences Inc - Iopofosine I 131 Well Tolerated With Consistent Toxicity Profile

THOMSON REUTERS
·
11 Jun

Cellectar Biosciences Provides Update on Clover-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients With Relapsed/Refractory High-Grade Glioma

THOMSON REUTERS
·
11 Jun

Cellectar Biosciences Expects to Raise $2.5 Million via Stock Sale, Warrant Exercise

MT Newswires Live
·
05 Jun

Cellectar Biosciences enters common stock agreements to raise $2.5M

TIPRANKS
·
05 Jun

Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May

Benzinga
·
05 Jun

Cellectar Biosciences Says FDA Granted Breakthrough Therapy Designation for Experimental Cancer Drug; Shares Rise Pre-Bell

MT Newswires Live
·
04 Jun

Cellectar Biosciences - Seeks Ema Guidance for Fast-Track Marketing Authorization, Ema Recommendation Expected Late July 2025

THOMSON REUTERS
·
04 Jun

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (Wm)

THOMSON REUTERS
·
04 Jun

Cellectar Biosciences Inc - Clover Wam Phase 2 Study Data Shows 83.6% Overall Response Rate

THOMSON REUTERS
·
04 Jun

Cellectar Biosciences Cut to Hold From Buy by Maxim Group

Dow Jones
·
15 May

Cellectar Biosciences Inc : Maxim Group Cuts to Hold From Buy

THOMSON REUTERS
·
14 May

Cellectar Biosciences Reports Q1 2025 Financials and Strategic Plans

TIPRANKS
·
14 May

Cellectar Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Cellectar Biosciences Q1 EPS $(0.14) Beats $(0.16) Estimate, Cash $13.9M

Benzinga
·
13 May

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
13 May

Cellectar Biosciences Q1 EPS USD -0.14

THOMSON REUTERS
·
13 May

Cellectar Biosciences Q1 Net Income USD -6.6 Million

THOMSON REUTERS
·
13 May

Press Release: Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Dow Jones
·
13 May